Global Initiative for Chronic Obstructive Lung Disease

POCKET GUIDE TO COPD DIAGNOSIS, MANAGEMENT, AND PREVENTION
A Guide for Health Care Professionals
2019 REPORT
GOLD BOARD OF DIRECTORS (2018)

Alvar Agusti, MD, Chair
Respiratory Institute, Hospital Clinic, IDIBAPS
Univ. Barcelona and Ciberes
Barcelona, Spain

Bartolome R. Celli, MD
Brigham and Women’s Hospital
Boston, Massachusetts, USA

Rongchang Chen, MD
Guangzhou Institute of Respiratory Disease
Guangzhou, PRC

Gerard Criner, MD
Temple University School of Medicine
Philadelphia, Pennsylvania, USA

Peter Frith, MD
Flinders Hospital
Adelaide, Australia

David Halpin, MD
Royal Devon and Exeter Hospital
Devon, UK

M. Victorina López Varela, MD
Universidad de la República
Montevideo, Uruguay

Masaharu Nishimura, MD (retired May, 2018)
Hokkaido University School of Medicine
Sapporo, Japan

Sundeep Salvi, MD
Chest Research Foundation
Pune, India

Claus Vogelmeier, MD
University of Marburg
Marburg, Germany

GOLD SCIENCE COMMITTEE* (2018)

Claus Vogelmeier, MD, Chair
University of Marburg
Marburg, Germany

Alvar Agusti, MD
Respiratory Institute, Hospital Clinic, IDIBAPS
Univ. Barcelona and Ciberes
Barcelona, Spain

Antonio Anzueto, MD
University of Texas Health Science Center
San Antonio, Texas, USA

Peter Barnes, MD
National Heart and Lung Institute
London, United Kingdom

Jean Bourbeau, MD
McGill University Health Centre
Montreal, Canada

Gerard Criner, MD
Temple University School of Medicine
Philadelphia, Pennsylvania, USA

Maria Modes de Oca, MD
Hospital Universitario de Caracas
Caracas, Venezuela

Peter Frith, MD
Repatriation General Hospital
Adelaide, Australia

David Halpin, MD
Royal Devon and Exeter Hospital
Devon, United Kingdom

MeiLan Han, MD MS
University of Michigan
Ann Arbor, MI, USA

GOLD PROGRAM DIRECTOR

Rebecca Decker, MSJ
Fontana, Wisconsin, USA

EDITORIAL ASSISTANCE

Ruth Hadfield, PhD, Sydney, Australia
Michael Hess, RRT RPFT, Michigan, USA

 Disclosure forms for GOLD Committees are posted on the GOLD Website, www.goldcopd.org
# TABLE OF CONTENTS

TABLE OF CONTENTS .......................................................... III

GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF COPD........1

INTRODUCTION ................................................................. 1

DEFINITION AND OVERVIEW ............................................... 1

OVERALL KEY POINTS: ....................................................... 1
WHAT IS CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)? ............................................. 2
WHAT CAUSES COPD? ........................................................ 2

DIAGNOSIS AND ASSESSMENT OF COPD ......................... 4

OVERALL KEY POINTS: ....................................................... 4
DIAGNOSIS ................................................................. 4
DIFFERENTIAL DIAGNOSIS ................................................ 4
ASSESSMENT ................................................................. 5
Classification of severity of airflow limitation ....... 5
Assessment of symptoms ............................................... 8
Combined COPD assessment ....................................... 8

EVIDENCE SUPPORTING PREVENTION AND MAINTENANCE THERAPY ............................ 9

OVERALL KEY POINTS: ....................................................... 9
SMOKING CESSATION ...................................................... 10
VACCINATIONS ............................................................ 10
PHARMACOLOGICAL THERAPY FOR STABLE COPD .......... 12
Overview of the medications .................................. 11
Bronchodilators ......................................................... 11
Antimuscarinic drugs ............................................... 12
Methyloxanthines ...................................................... 14
Combination bronchodilator therapy ..................... 14
Anti-inflammatory agents ...................................... 15
Inhaled corticosteroids (ICS) ................................ 15
Triple inhaled therapy ............................................ 19
Oral glucocorticoids ............................................... 19
Phosphodiesterase-4 (PDE4) inhibitors ................. 19
Antibiotics ............................................................... 19
Mucolytic (mucokinetics, mucoregulators) and antioxidant agents (NAC, carbocysteine) .... 20
Issues related to inhaled delivery ......................... 20
Other pharmacological treatments ..................... 20

REHABILITATION, EDUCATION & SELF-MANAGEMENT .............................................. 21
Pulmonary rehabilitation ............................................. 21

SUPPORTIVE, PALLIATIVE, END-OF-LIFE & HOSPICE CARE ........................................ 21
Symptom control and palliative care ................. 21

OTHER TREATMENTS .......................................................... 22
Oxygen therapy and ventilatory support .......... 22
Ventilatory Support .................................................. 22
Surgical Interventions .............................................. 23

MANAGEMENT OF STABLE COPD ........................................ 24

OVERALL KEY POINTS: ....................................................... 24
IDENTIFY AND REDUCE EXPOSURE TO RISK FACTORS ......................................................... 24
TREATMENT OF STABLE COPD: PHARMACOCOLICAL TREATMENT ..................................... 25
Algorithms for the assessment, initiation and follow-up management of pharmacological treatment ..................... 27
TREATMENT OF STABLE COPD: NON-PHARMACOCOLICAL TREATMENT .................. 33
Education and self-management ......................... 33
Oxygen therapy ......................................................... 34
MONITORING AND FOLLOW-UP ......................................... 36

MANAGEMENT OF EXACERBATIONS ........................................ 36

OVERALL KEY POINTS: ....................................................... 36
TREATMENT OPTIONS ................................................... 37
Treatment setting .................................................... 37
Respiratory support ................................................. 39
Hospital discharge and follow-up .................... 41
Prevention of exacerbations ............................ 43

COPD AND COMORBIDITIES .............................................. 44

OVERALL KEY POINTS: ....................................................... 44
REFERENCES ............................................................... 44
GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF COPD

INTRODUCTION

Chronic Obstructive Pulmonary Disease (COPD) is currently the fourth leading cause of death in the world\(^1\) but is projected to be the 3\(^{rd}\) leading cause of death by 2020. More than 3 million people died of COPD in 2012 accounting for 6\% of all deaths globally. COPD represents an important public health challenge that is both preventable and treatable. COPD is a major cause of chronic morbidity and mortality throughout the world; many people suffer from this disease for years, and die prematurely from it or its complications. Globally, the COPD burden is projected to increase in coming decades because of continued exposure to COPD risk factors and aging of the population.\(^2\)

This Pocket Guide has been developed from the Global Strategy for the Diagnosis, Management, and Prevention of COPD (2019 Report), which aims to provide a non-biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD that can aid the clinician. Discussions of COPD and COPD management, evidence levels, and specific citations from the scientific literature are included in that source document, which is available from www.goldcopd.org.

DEFINITION AND OVERVIEW

OVERALL KEY POINTS:

- Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases.

- The most common respiratory symptoms include dyspnea, cough and/or sputum production. These symptoms may be under-reported by patients.

- The main risk factor for COPD is tobacco smoking but other environmental exposures such as biomass fuel exposure and air pollution may contribute. Besides exposures, host factors predispose individuals to develop COPD. These include genetic abnormalities, abnormal lung development and accelerated aging.

- COPD may be punctuated by periods of acute worsening of respiratory symptoms, called exacerbations.

- In most patients, COPD is associated with significant concomitant chronic diseases, which increase its morbidity and mortality.
WHAT IS CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)?

Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases. The chronic airflow limitation that is characteristic of COPD is caused by a mixture of small airways disease (e.g., obstructive bronchiolitis) and parenchymal destruction (emphysema), the relative contributions of which vary from person to person (see Figure).

WHAT CAUSES COPD?

Worldwide, the most commonly encountered risk factor for COPD is tobacco smoking. Nonsmokers may also develop COPD. COPD is the result of a complex interplay of long-term cumulative exposure to noxious gases and particles, combined with a variety of host factors including genetics, airway hyper-responsiveness and poor lung growth during childhood. The risk of developing COPD is related to the following factors:

- **Tobacco smoke** – cigarette smokers have a higher prevalence of respiratory symptoms and
l lung function abnormalities, a greater annual rate of decline in FEV₁, and a greater COPD mortality rate than non-smokers. Other types of tobacco (e.g., pipe, cigar, water pipe) and marijuana are also risk factors for COPD, as well as environmental tobacco smoke (ETS).

► **Indoor air pollution** – resulting from the burning of wood and other biomass fuels used for cooking and heating in poorly vented dwellings, is a risk factor that particularly affects women in developing countries.

► **Occupational exposures** – including organic and inorganic dusts, chemical agents and fumes, are under-appreciated risk factors for COPD.

► **Outdoor air pollution** – also contributes to the lungs’ total burden of inhaled particles, although it appears to have a relatively small effect in causing COPD.

► **Genetic factors** – such as severe hereditary deficiency of alpha-1 antitrypsin (AATD); the gene encoding matrix metalloproteinase 12 (MMP-12) and glutathione S-transferase have also been related to a decline in lung function or risk of COPD.

► **Age and sex** – aging and female sex increase COPD risk.

► **Lung growth and development** – any factor that affects lung growth during gestation and childhood (low birth weight, respiratory infections, etc.) has the potential to increase an individual’s risk of developing COPD.

► **Socioeconomic status** – Poverty is consistently associated with airflow obstruction and lower socioeconomic status is associated with an increased risk of developing COPD. It is not clear, however, whether this pattern reflects exposures to indoor and outdoor air pollutants, crowding, poor nutrition, infections, or other factors related to low socioeconomic status.

► **Asthma and airway hyper-reactivity** – asthma may be a risk factor for the development of airflow limitation and COPD.

► **Chronic bronchitis** – may increase the frequency of total and severe exacerbations.

► **Infections** – a history of severe childhood respiratory infection has been associated with reduced lung function and increased respiratory symptoms in adulthood.
DIAGNOSIS AND ASSESSMENT OF COPD

OVERALL KEY POINTS:

• COPD should be considered in any patient who has dyspnea, chronic cough or sputum production, a history of recurrent lower respiratory tract infections and/or a history of exposure to risk factors for the disease.

• Spirometry is required to make the diagnosis; the presence of a post-bronchodilator FEV₁/FVC < 0.70 confirms the presence of persistent airflow limitation.

• The goals of COPD assessment are to determine the level of airflow limitation, the impact of disease on the patient’s health status, and the risk of future events (such as exacerbations, hospital admissions, or death), in order to guide therapy.

• Concomitant chronic diseases occur frequently in COPD patients, including cardiovascular disease, skeletal muscle dysfunction, metabolic syndrome, osteoporosis, depression, anxiety, and lung cancer. These comorbidities should be actively sought and treated appropriately when present as they can influence mortality and hospitalizations independently.

DIAGNOSIS

COPD should be considered in any patient who has dyspnea, chronic cough or sputum production, and/or a history of exposure to risk factors for the disease (see Table). Spirometry is required to make the diagnosis in this clinical context; the presence of a post-bronchodilator FEV₁/FVC < 0.70 confirms the presence of persistent airflow limitation and thus of COPD in patients with appropriate symptoms and significant exposures to noxious stimuli. Spirometry is the most reproducible and objective measurement of airflow limitation. It is a noninvasive and readily available test. Despite its good sensitivity, peak expiratory flow measurement alone cannot be reliably used as the only diagnostic test because of its weak specificity.

DIFFERENTIAL DIAGNOSIS

A major differential diagnosis is asthma. In some patients with chronic asthma, a clear distinction from COPD is not possible using current imaging and physiological testing techniques. In these patients, current management is similar to that of asthma. Other potential diagnoses are usually easier to distinguish from COPD (see Table).

Alpha-1 antitrypsin deficiency (AATD) screening. The World Health Organization recommends that all patients with a diagnosis of COPD should be screened once especially in areas with high AATD prevalence. A low concentration (< 20% normal) is highly suggestive of homozygous deficiency. Family members should also be screened.
The goals of COPD assessment are to determine the level of airflow limitation, its impact on the patient’s health status and the risk of future events (such as exacerbations, hospital admissions or death), in order to, eventually, guide therapy. To achieve these goals, COPD assessment must consider the following aspects of the disease separately:

- The presence and severity of the spirometric abnormality
- Current nature and magnitude of the patient’s symptoms
- History of moderate and severe exacerbations and future risk
- Presence of comorbidities

**Classification of severity of airflow limitation**

The classification of airflow limitation severity in COPD (see Table) uses specific spirometric cut-points for purposes of simplicity. Spirometry should be performed after the administration of an adequate dose of at least one short-acting inhaled bronchodilator in order to minimize variability.

It should be noted that there is only a weak correlation between FEV₁, symptoms and impairment of a patient’s health status. For this reason, formal symptomatic assessment is required.
# Differential Diagnosis of COPD

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Suggestive Features</th>
</tr>
</thead>
<tbody>
<tr>
<td>COPD</td>
<td>Onset in mid-life. Symptom slowly progressive. History of tobacco smoking or exposure to other types of smoke.</td>
</tr>
<tr>
<td>Asthma</td>
<td>Onset early in life (often childhood). Symptoms vary widely from day to day. Symptoms worse at night/early morning. Allergy, rhinitis, and/or eczema also present. Family history of asthma. Obesity coexistence.</td>
</tr>
<tr>
<td>Congestive Heart Failure</td>
<td>Chest X-ray shows dilated heart, pulmonary edema. Pulmonary function tests indicate volume restriction, not airflow limitation.</td>
</tr>
<tr>
<td>Bronchiectasis</td>
<td>Large volumes of purulent sputum. Commonly associated with bacterial infection. Chest X-ray/CT shows bronchial dilation, bronchial wall thickening.</td>
</tr>
<tr>
<td>Obliterative Bronchiolitis</td>
<td>Onset at younger age, non-smokers. May have history of rheumatoid arthritis or acute fume exposure. Seen after lung or bone marrow transplantation. CT on expiration shows hypodense areas.</td>
</tr>
<tr>
<td>Diffuse Panbronchiolitis</td>
<td>Predominantly seen in patients of Asian descent. Most patients are male and non-smokers. Almost all have chronic sinusitis. Chest X-ray &amp; HRCT show diffuse small centrilobular nodular opacities &amp; hyperinflation.</td>
</tr>
</tbody>
</table>

*These features tend to be characteristic of the respective diseases, but are not mandatory. For example, a person who has never smoked may develop COPD (especially in the developing world where other risk factors may be more important than cigarette smoking); asthma may develop in adult and even in elderly patients.*

## Classification of Airflow Limitation Severity in COPD (Based on Post-Bronchodilator FEV₁)

In patients with FEV₁/FVC < 0.70:

<table>
<thead>
<tr>
<th>GOLD 1:</th>
<th>Mild</th>
<th>FEV₁ ≥ 80% predicted</th>
</tr>
</thead>
<tbody>
<tr>
<td>GOLD 2:</td>
<td>Moderate</td>
<td>50% ≤ FEV₁ &lt; 80% predicted</td>
</tr>
<tr>
<td>GOLD 3:</td>
<td>Severe</td>
<td>30% ≤ FEV₁ &lt; 50% predicted</td>
</tr>
<tr>
<td>GOLD 4:</td>
<td>Very Severe</td>
<td>FEV₁ &lt; 30% predicted</td>
</tr>
</tbody>
</table>
## MODIFIED MRC DYSPEANEA SCALE

**PLEASE TICK IN THE BOX THAT APPLIES TO YOU | ONE BOX ONLY | Grades 0 - 4**

| mMRC Grade 0. | I only get breathless with strenuous exercise. |
| mMRC Grade 1. | I get short of breath when hurrying on the level or walking up a slight hill. |
| mMRC Grade 2. | I walk slower than people of the same age on the level because of breathlessness, or I have to stop for breath when walking on my own pace on the level. |
| mMRC Grade 3. | I stop for breath after walking about 100 meters or after a few minutes on the level. |
| mMRC Grade 4. | I am too breathless to leave the house or I am breathless when dressing or undressing. |


## CAT™ ASSESSMENT

*For each item below, place a mark (X) in the box that best describes you currently. Be sure to only select one response for each question.*

<table>
<thead>
<tr>
<th>EXAMPLE: I am very happy</th>
<th>I am very sad</th>
<th>SCORE</th>
</tr>
</thead>
<tbody>
<tr>
<td>I never cough</td>
<td>0 12345</td>
<td>0 12345</td>
</tr>
<tr>
<td>I have no phlegm (mucus) in my chest at all</td>
<td>0 12345</td>
<td>0 12345</td>
</tr>
<tr>
<td>My chest does not feel tight at all</td>
<td>0 12345</td>
<td>0 12345</td>
</tr>
<tr>
<td>When I walk up a hill or one flight of stairs I am not breathless</td>
<td>0 12345</td>
<td>0 12345</td>
</tr>
<tr>
<td>I am not limited doing any activities at home</td>
<td>0 12345</td>
<td>0 12345</td>
</tr>
<tr>
<td>I am confident leaving my home despite my lung condition</td>
<td>0 12345</td>
<td>0 12345</td>
</tr>
<tr>
<td>I sleep soundly</td>
<td>0 12345</td>
<td>0 12345</td>
</tr>
<tr>
<td>I have lots of energy</td>
<td>0 12345</td>
<td>0 12345</td>
</tr>
</tbody>
</table>

Reference: Jones et al. ERJ 2009; 34 (3); 648-54.

**FIGURE 2.3**
**Assessment of symptoms**

In the past, COPD was viewed as a disease largely characterized by breathlessness. A simple measure of breathlessness such as the Modified British Medical Research Council (mMRC) Questionnaire (see Table) was considered adequate for assessment of symptoms, as the mMRC relates well to other measures of health status and predicts future mortality risk. However, it is now recognized that COPD impacts patients beyond just dyspnea. For this reason, a comprehensive assessment of symptoms is recommended using measures such as the COPD Assessment Test (CAT™) (see Figure) and The COPD Control Questionnaire (The CCQ).

**Combined COPD assessment**

An understanding of the impact of COPD on an individual patient combines the symptomatic assessment with the patient’s spirometric classification and/or risk of exacerbations. In the revised assessment scheme (see Figure), patients should undergo spirometry to determine the severity of airflow limitation (i.e., spirometric grade). They should also undergo assessment of either dyspnea using mMRC or symptoms using CAT™. Finally, their history of moderate and severe exacerbations (including prior hospitalizations) should be recorded.

The number provides information regarding severity of airflow limitation (spirometric grade 1 to 4) while the letter (groups A to D) provides information regarding symptom burden and risk of exacerbation which can be used to guide therapy.

---

**THE REFINED ABCD ASSESSMENT TOOL**

- Spirometrically Confirmed Diagnosis
- Assessment of airflow limitation
- Assessment of symptoms/risk of exacerbations

**Moderate or Severe Exacerbation History**

- ≥2 or ≥ 1 leading to hospital admission
- 0 or 1 (not leading to hospital admission)

**Grade**

<table>
<thead>
<tr>
<th>Grade</th>
<th>FEV₁ (% predicted)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GOLD 1</td>
<td>≥ 80</td>
</tr>
<tr>
<td>GOLD 2</td>
<td>50-79</td>
</tr>
<tr>
<td>GOLD 3</td>
<td>30-49</td>
</tr>
<tr>
<td>GOLD 4</td>
<td>&lt; 30</td>
</tr>
</tbody>
</table>

**Symptoms**

- mMRC 0-1: CAT < 10
- mMRC ≥ 2: CAT ≥ 10

**Example**: Consider two patients - both patients with FEV₁ < 30% of predicted, CAT™ scores of 18 and
one with no exacerbations in the past year and the other with three moderate exacerbations in the past year. Both would have been labelled GOLD D in the prior classification scheme. However, with the new proposed scheme, the subject with three moderate exacerbations in the past year would be labelled GOLD grade 4, group D.

EVIDENCE SUPPORTING PREVENTION AND MAINTENANCE THERAPY

OVERALL KEY POINTS:

• Smoking cessation is key. Pharmacotherapy and nicotine replacement reliably increase long-term smoking abstinence rates. Legislative smoking bans and counselling, delivered by healthcare professionals improve quit rates.

• The effectiveness and safety of e-cigarettes as a smoking cessation aid is uncertain at present.

• Pharmacological therapy can reduce COPD symptoms, reduce the frequency and severity of exacerbations, and improve health status and exercise tolerance.

• Each pharmacological treatment regimen should be individualized and guided by the severity of symptoms, risk of exacerbations, side-effects, comorbidities, drug availability and cost, and the patient’s response, preference and ability to use various drug delivery devices.

• Inhaler technique needs to be assessed regularly.

• Influenza vaccination decreases the incidence of lower respiratory tract infections.

• Pneumococcal vaccination decreases lower respiratory tract infections.

• Pulmonary rehabilitation improves symptoms, quality of life, and physical and emotional participation in everyday activities.

• In patients with severe resting chronic hypoxemia, long-term oxygen therapy improves survival.

• In patients with stable COPD and resting or exercise-induced moderate desaturation, long-term oxygen treatment should not be prescribed routinely. However, individual patient factors must be considered when evaluating the patient’s need for supplemental oxygen.

• In patients with severe chronic hypercapnia and a history of hospitalization for acute respiratory failure, long-term non-invasive ventilation may decrease mortality and prevent re-hospitalization.

• In select patients with advanced emphysema refractory to optimized medical care, surgical or bronchoscopic interventional treatments may be beneficial.

• Palliative approaches are effective in controlling symptoms in advanced COPD.
SMOKING CESSATION

Smoking cessation has the greatest capacity to influence the natural history of COPD. If effective resources and time are dedicated to smoking cessation, long-term quit success rates of up to 25% can be achieved.\textsuperscript{34} Besides individual approaches to smoking cessation, legislative smoking bans are effective in increasing quit rates and reducing harm from second-hand smoke exposure.\textsuperscript{35} A five-step program for intervention (see Table)\textsuperscript{36-38} provides a helpful strategic framework.\textsuperscript{36,38,39}

BRIEF STRATEGIES TO HELP THE PATIENT WILLING TO QUIT

- **ASK:** Systematically identify all tobacco users at every visit. Implement an office-wide system that ensures that, for EVERY patient at EVERY clinic visit, tobacco-use status is queried and documented.

- **ADVISE:** Strongly urge all tobacco users to quit. In a clear, strong, and personalized manner, urge every tobacco user to quit.

- **ASSESS:** Determine willingness and rationale of patient’s desire to make a quit attempt. Ask every tobacco user if he or she is willing to make a quit attempt at this time (e.g., within the next 30 days).

- **ASSIST:** Aid the patient in quitting. Help the patient with a quit plan; provide practical counseling; provide intra-treatment social support; help the patient obtain extra-treatment social support; recommend use of approved pharmacotherapy except in special circumstances; provide supplementary materials.

- **ARRANGE:** Schedule follow-up contact. Schedule follow-up contact, either in person or via telephone.

VACCINATIONS

VACCINATION FOR STABLE COPD

- Influenza vaccination reduces serious illness and death in COPD patients (Evidence B).

- The 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been shown to reduce the incidence of community-acquired pneumonia in COPD patients aged < 65 years with an FEV\textsubscript{1} < 40% predicted and in those with comorbidities (Evidence B).

- In the general population of adults ≥65 years the 13-valent conjugated pneumococcal vaccine (PCV13) has demonstrated significant efficacy in reducing bacteremia & serious invasive pneumococcal disease (Evidence B).
PHARMACOLOGICAL THERAPY FOR STABLE COPD

Overview of the medications

Pharmacological therapy for COPD is used to reduce symptoms, reduce the frequency and severity of exacerbations, and improve exercise tolerance and health status. The classes of medications commonly used to treat COPD are shown in the Table. To date, there is no conclusive clinical trial evidence that any existing medications for COPD modify the long-term decline in lung function. Post-hoc evidence of such an effect with long-acting bronchodilators and/or inhaled corticosteroids requires confirmation in specifically designed trials.

Bronchodilators

Bronchodilators are medications that increase FEV1 and/or change other spirometric variables.

► Bronchodilator medications in COPD are most often given on a regular basis to prevent or reduce symptoms.
► Toxicity is also dose-related.
► Use of short acting bronchodilators on a regular basis is not generally recommended.

Beta2-agonists

► The principal action of beta2-agonists is to relax airway smooth muscle by stimulating beta2-adrenergic receptors, which increases cyclic AMP and produces functional antagonism to bronchoconstriction.
► There are short-acting (SABA) and long-acting (LABA) beta2-agonists. The effect of SABAs usually wears off within 4 to 6 hours. Regular and as-needed use of SABAs improve FEV1 and symptoms.
► For single-dose, as-needed use in COPD, there appears to be no advantage in routinely using levalbuterol over conventional bronchodilators. LABAs show duration of action of 12 or more hours and do not preclude additional benefit from as-needed SABA therapy.
► Formoterol and salmeterol are twice-daily LABAs that significantly improve FEV1 and lung volumes, dyspnea, health status, exacerbation rate and number of hospitalizations, but have no effect on mortality or rate of decline of lung function.
► Indacaterol is a once daily LABA that improves breathlessness, health status and exacerbation rate. Some patients experience cough following the inhalation of indacaterol.
► Olodaterol and vilanterol are additional once daily LABAs that improve lung function and symptoms.

Adverse effects. Stimulation of beta2-adrenergic receptors can produce resting sinus tachycardia and has the potential to precipitate cardiac rhythm disturbances in susceptible patients. Exaggerated somatic tremor is troublesome in some older patients treated with higher doses of beta2-agonists, regardless of route of administration. Although hypokalemia can occur, especially when treatment is combined with thiazide diuretics, and oxygen consumption can be increased under resting conditions in patients with chronic heart failure, these metabolic effects decrease over time (i.e., show tachyphylaxis). Mild falls in partial pressure of oxygen (PaO2) can occur after administration of both SABAs and LABAs but the clinical significance of these changes is uncertain. Despite prior
concerns related to the use of beta_2-agonists in the management of asthma, no association between beta_2-agonist use and loss of lung function or increased mortality has been reported in COPD.\textsuperscript{52,60,61}

**Antimuscarinic drugs**

- Antimuscarinic drugs block the bronchoconstrictor effects of acetylcholine on M3 muscarinic receptors expressed in airway smooth muscle.\textsuperscript{62}
- Short-acting antimuscarinics (SAMAs), namely ipratropium and oxitropium, also block the inhibitory neuronal receptor M2, which potentially can cause vagally induced bronchoconstriction.\textsuperscript{63}
- Long-acting antimuscarinic antagonists (LAMAs), such as tiotropium, aclidinium, glycopyrronium bromide and umeclidinium have prolonged binding to M3 muscarinic receptors, with faster dissociation from M2 muscarinic receptors, thus prolonging the duration of bronchodilator effect.\textsuperscript{62}
- A systematic review of randomized controlled trials concluded that ipratropium, a short acting muscarinic antagonist, alone provided small benefits over short-acting beta_2-agonist in terms of lung function, health status and requirement for oral steroids.\textsuperscript{64}
- LAMA treatments (tiotropium) improve symptoms and health status.\textsuperscript{62,65} They also improve the effectiveness of pulmonary rehabilitation\textsuperscript{66,67} and reduce exacerbations and related hospitalizations.\textsuperscript{65}
- Clinical trials have shown a greater effect on exacerbation rates for LAMA treatment (tiotropium) versus LABA treatment.\textsuperscript{68,69}

**Adverse effects.** Inhaled anticholinergic drugs are poorly absorbed which limits the troublesome systemic effects observed with atropine.\textsuperscript{62,70} Extensive use of this class of agents in a wide range of doses and clinical settings has shown them to be very safe. The main side effect is dryness of mouth.\textsuperscript{63,71} Although occasional urinary symptoms have been reported, there are no data to prove a true causal relationship.\textsuperscript{72} Some patients using ipratropium report a bitter, metallic taste. An unexpected small increase in cardiovascular events in COPD patients regularly treated with ipratropium bromide has been reported.\textsuperscript{73,74} In a large, long-term clinical trial in COPD patients, tiotropium added to other standard therapies had no effect on cardiovascular risk.\textsuperscript{44} Although there were some initial concerns regarding the safety of tiotropium delivery via the Respimat\textsuperscript{®} inhaler, the findings of a large trial observed no difference in mortality or exacerbation rates when comparing tiotropium in a dry-powder inhaler and the Respimat\textsuperscript{®} inhaler.\textsuperscript{76}
# COMMONLY USED MAINTENANCE MEDICATIONS IN COPD*

<table>
<thead>
<tr>
<th>Generic Drug Name</th>
<th>Inhaler Type</th>
<th>Nebulizer</th>
<th>Oral</th>
<th>Injection</th>
<th>Duration Of Action</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BETA₂-AGONISTS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SHORT-ACTING (SABA)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fenoterol</td>
<td>MDI</td>
<td>✓</td>
<td></td>
<td>pill, syrup</td>
<td>4-6 hours</td>
</tr>
<tr>
<td>Levalbuterol</td>
<td>MDI</td>
<td>✓</td>
<td></td>
<td></td>
<td>6-8 hours</td>
</tr>
<tr>
<td>Salbutamol (albuterol)</td>
<td>MDI &amp; DPI</td>
<td>✓</td>
<td></td>
<td>pill, syrup, extended release tablet</td>
<td>4-6 hours (ext. release)</td>
</tr>
<tr>
<td>Terbutaline</td>
<td>DPI</td>
<td></td>
<td></td>
<td>pill</td>
<td>4-6 hours</td>
</tr>
<tr>
<td><strong>LONG-ACTING (LABA)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arformoterol</td>
<td></td>
<td>✓</td>
<td></td>
<td></td>
<td>12 hours</td>
</tr>
<tr>
<td>Formoterol</td>
<td>DPI</td>
<td></td>
<td></td>
<td></td>
<td>12 hours</td>
</tr>
<tr>
<td>Indacaterol</td>
<td>DPI</td>
<td></td>
<td></td>
<td></td>
<td>24 hours</td>
</tr>
<tr>
<td>Olopatadine</td>
<td>SMI</td>
<td></td>
<td></td>
<td></td>
<td>24 hours</td>
</tr>
<tr>
<td>Salmeterol</td>
<td>MDI &amp; DPI</td>
<td></td>
<td></td>
<td></td>
<td>12 hours</td>
</tr>
<tr>
<td><strong>ANTICHOLINERGICS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SHORT-ACTING (SAMO)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ipratropium bromide</td>
<td>MDI</td>
<td>✓</td>
<td></td>
<td></td>
<td>6-8 hours</td>
</tr>
<tr>
<td>Oxytropium bromide</td>
<td>MDI</td>
<td></td>
<td></td>
<td></td>
<td>7-9 hours</td>
</tr>
<tr>
<td><strong>LONG-ACTING (LAMA)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allocinabridine</td>
<td>DPI, MDI</td>
<td></td>
<td></td>
<td></td>
<td>12 hours</td>
</tr>
<tr>
<td>Glycopyrrolone bromide</td>
<td>DPI</td>
<td>solution</td>
<td>✓</td>
<td></td>
<td>12-24 hours</td>
</tr>
<tr>
<td>Tiotropium</td>
<td>DPI, SMI</td>
<td></td>
<td></td>
<td></td>
<td>24 hours</td>
</tr>
<tr>
<td>Umeclidinium</td>
<td>DPI</td>
<td></td>
<td></td>
<td></td>
<td>24 hours</td>
</tr>
<tr>
<td><strong>COMBINATION SHORT-ACTING BETA₂-AGONIST PLUS ANTICHOLINERGIC IN ONE DEVICE (SABA/SAMA)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fenoterol/Ipratropium</td>
<td>SMI</td>
<td>✓</td>
<td></td>
<td></td>
<td>6-8 hours</td>
</tr>
<tr>
<td>Salbutamol/Ipratropium</td>
<td>SMI, MDI</td>
<td></td>
<td></td>
<td></td>
<td>6-8 hours</td>
</tr>
<tr>
<td><strong>COMBINATION LONG-ACTING BETA₂-AGONIST PLUS ANTICHOLINERGIC IN ONE DEVICE (LABA/LAMA)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Formoterol/Allocinabridine</td>
<td>DPI</td>
<td></td>
<td></td>
<td></td>
<td>12 hours</td>
</tr>
<tr>
<td>Formoterol/Glycopyrrolone bromide</td>
<td>MDI</td>
<td></td>
<td></td>
<td></td>
<td>12 hours</td>
</tr>
<tr>
<td>Indacaterol/Glycopyrrolone bromide</td>
<td>DPI</td>
<td></td>
<td></td>
<td></td>
<td>12-24 hours</td>
</tr>
<tr>
<td>Vilanterol/Umeclidinium</td>
<td>DPI</td>
<td></td>
<td></td>
<td></td>
<td>24 hours</td>
</tr>
<tr>
<td>Olopatadine/Tiotropium</td>
<td>SMI</td>
<td></td>
<td></td>
<td></td>
<td>24 hours</td>
</tr>
<tr>
<td><strong>METHYLXANTHINES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aminophylline</td>
<td>solution</td>
<td>✓</td>
<td></td>
<td></td>
<td>Variable, up to 24 hours</td>
</tr>
<tr>
<td>Theophylline (SR)</td>
<td>pill</td>
<td>✓</td>
<td></td>
<td></td>
<td>Variable, up to 24 hours</td>
</tr>
<tr>
<td><strong>COMBINATION OF LONG-ACTING BETA₂-AGONIST PLUS CORTICOSTEROIDS IN ONE DEVICE (LABA/ICS)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Formoterol/Beclomethasone</td>
<td>MDI</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Formoterol/Budesonide</td>
<td>MDI, DPI</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Formoterol/Mometasone</td>
<td>MDI</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salmeterol/Fluticasone</td>
<td>MDI, DPI</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vilanterol/Fluticasone furoate</td>
<td>DPI</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TRIPLE COMBINATION IN ONE DEVICE (LABA/LAMA/ICS)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluticasone/Umeclidinium/vilanterol</td>
<td>DPI</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beclomethasone/Formoterol/Glycopyrrolone</td>
<td>MDI</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PHOSPHODIESTERASE-4 INHIBITORS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Roflumastat</td>
<td>pill</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MUCOLYTIC AGENTS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erdosteine</td>
<td>pill</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Not all formulations are available in all countries. In some countries other formulations and dosages may be available.

MDI = metered dose inhaler; DPI = dry powder inhaler; SMI = soft mist inhaler.
Methylxanthines

- Controversy remains about the exact effects of xanthine derivatives.
- Theophylline, the most commonly used methylxanthine, is metabolized by cytochrome P450 mixed function oxidases. Clearance of the drug declines with age.
- There is evidence for a modest bronchodilator effect compared with placebo in stable COPD.\textsuperscript{77}
- Addition of theophylline to salmeterol produces a greater improvement in FEV\textsubscript{1} and breathlessness than salmeterol alone.\textsuperscript{78,79}
- There is limited and contradictory evidence regarding the effect of low-dose theophylline on exacerbation rates.\textsuperscript{80,81}

Adverse effects. Toxicity is dose-related, which is a particular problem with xanthine derivatives because their therapeutic ratio is small and most of the benefit occurs only when near-toxic doses are given.\textsuperscript{77,82}

Combination bronchodilator therapy

Combining bronchodilators with different mechanisms and durations of action may increase the degree of bronchodilation with a lower risk of side-effects compared to increasing the dose of a single bronchodilator.\textsuperscript{83} Combinations of SABAs and SAMAs are superior compared to either medication alone in improving FEV\textsubscript{1} and symptoms.\textsuperscript{84} Treatment with formoterol and tiotropium in separate inhalers has a bigger impact on FEV\textsubscript{1} than either component alone.\textsuperscript{85} There are numerous combinations of a LABA and LAMA in a single inhaler available. These combinations improve lung function compared to placebo\textsuperscript{83}; this improvement is consistently greater than long acting bronchodilator monotherapy effects although the magnitude of improvement is less than the fully additive effect predicted by the individual component responses.\textsuperscript{86} In studies where patient reported outcomes (PROs) are the primary endpoint or in pooled analyses, combination bronchodilators have a greater impact on PROs compared to monotherapies.\textsuperscript{87-90} In one clinical trial, combination LABA/LAMA treatment had the greatest improvement in quality of life compared to placebo or its individual bronchodilator components in patients with a greater baseline symptom burden.\textsuperscript{91} These clinical trials deal with group mean data, but symptom responses to LABA/LAMA combinations are best evaluated on an individual patient basis. A lower dose, twice daily regimen for a LABA/LAMA has also been shown to improve symptoms and health status in COPD patients\textsuperscript{92} (see Table). These findings have been shown in people across different ethnic groups (Asian as well as European).\textsuperscript{93}

Most studies with LABA/LAMA combinations have been performed in patients with a low rate of exacerbations. One study in patients with a history of exacerbations indicated that a combination of long-acting bronchodilators is more effective than long-acting bronchodilator monotherapy for preventing exacerbations.\textsuperscript{94} Another large study found that combining a LABA with a LAMA did not reduce exacerbation rate as much as expected compared with a LAMA alone.\textsuperscript{95} Another study in patients with a history of exacerbations confirmed that a combination LABA/LAMA decreased exacerbations to a greater extent than an ICS/LABA combination.\textsuperscript{96} However, another study in a population with high exacerbation risk (≥ 2 exacerbations and/or 1 hospitalization in the previous year) reported that ICS/LABA decreased exacerbations to a greater extent than an LABA/LAMA combination at higher blood eosinophil concentrations.\textsuperscript{97}
Anti-inflammatory agents

To date, exacerbations (e.g., exacerbation rate, patients with at least one exacerbation, time-to-first exacerbation) represent the main clinically relevant end-point used for efficacy assessment of drugs with anti-inflammatory effects (see Table).

Inhaled corticosteroids (ICS)

**Preliminary general considerations.** In vitro evidence suggests that COPD-associated inflammation has limited responsiveness to corticosteroids. Moreover, some drugs including beta₂-agonists, theophylline or macrolides may partially facilitate corticosteroid sensitivity in COPD.⁹⁸,⁹⁹ The clinical relevance of this effect has not yet been fully established.

In vivo data suggest that the dose-response relationships and long-term (> 3 years) safety of inhaled corticosteroids (ICS) in patients with COPD are unclear and require further investigation.¹⁰⁰ Because the effects of ICS in COPD can be modulated by the concomitant use of long-acting bronchodilators, these two therapeutic options are discussed separately.

**Efficacy of ICS (alone).** Most studies have found that regular treatment with ICS alone does not modify the long-term decline of FEV₁ nor mortality in patients with COPD.¹⁰⁰ Studies and meta-analyses assessing the effect of regular treatment with ICS alone on mortality in patients with COPD have not provided conclusive evidence of benefit.¹⁰⁰ In the TORCH trial, a trend toward higher
mortality was observed for patients treated with fluticasone propionate alone compared to those receiving placebo or salmeterol plus fluticasone propionate combination.\textsuperscript{101} However, an increase in mortality was not observed in COPD patients treated with fluticasone furoate in the Survival in Chronic Obstructive Pulmonary Disease with Heightened Cardiovascular Risk (SUMMIT) trial.\textsuperscript{102} However, in moderate COPD, fluticasone furoate alone or in combination with vilanterol was associated with slower decline in FEV\textsubscript{1} compared with placebo or vilanterol alone by on average 9 ml/year.\textsuperscript{103}

### ANTI-INFLAMMATORY THERAPY IN STABLE COPD

#### INHALED CORTICOSTEROIDS

- An ICS combined with a LABA is more effective than the individual components in improving lung function and health status and reducing exacerbations in patients with exacerbations and moderate to very severe COPD (Evidence A).
- Regular treatment with ICS increases the risk of pneumonia especially in those with severe disease (Evidence A).
- Triple inhaled therapy of ICS/LAMA/LABA improves lung function, symptoms and health status and reduces exacerbations compared to ICS/LABA, LABA/LAMA or LAMA monotherapy (Evidence A).

#### ORAL GLUCOCORTICOSTEROIDS

- Long-term use of oral glucocorticoids has numerous side effects (Evidence A) with no evidence of benefits (Evidence C).

#### PDE4 INHIBITORS

- In patients with chronic bronchitis, severe to very severe COPD and a history of exacerbations:
  - A PDE4 inhibitor improves lung function and reduces moderate and severe exacerbations (Evidence A).
  - A PDE4 inhibitor improves lung function and decreases exacerbations in patients who are on fixed-dose LABA/ICS combinations (Evidence A).

#### ANTIBIOTICS

- Long-term azithromycin and erythromycin therapy reduces exacerbations over one year (Evidence A).
- Treatment with azithromycin is associated with an increased incidence of bacterial resistance (Evidence A) and hearing test impairments (Evidence B).

#### MUCOREGULATORS AND ANTIOXIDANT AGENTS

- Regular treatment with mucolytics such as erdosteine, carbocysteine and NAC reduces the risk of exacerbations in select populations (Evidence B).

#### OTHER ANTI-INFLAMMATORY AGENTS

- Simvastatin does not prevent exacerbations in COPD patients at increased risk of exacerbations and without indications for statin therapy (Evidence A). However, observational studies suggest that statins may have positive effects on some outcomes in patients with COPD who receive them for cardiovascular and metabolic indications (Evidence C).
- Leukotriene modifiers have not been tested adequately in COPD patients.

**ICS in combination with long-acting bronchodilator therapy.** In patients with moderate to very severe COPD and exacerbations, an ICS combined with a LABA is more effective than either component alone in improving lung function, health status and reducing exacerbations.\textsuperscript{104,105} Clinical
trials powered on all-cause mortality as the primary outcome failed to demonstrate a statistically significant effect of combination therapy on survival.\(^{101,102}\)

Most studies that found a beneficial effect of LABA/ICS fixed dose combination (FDC) over LABA alone on exacerbation rate, recruited patients with a history of at least one exacerbation in the previous year.\(^{104}\) A pragmatic RCT conducted in a primary healthcare setting in the United Kingdom compared a LABA/ICS combination with usual care. Findings showed an 8.4% reduction in moderate-to-severe exacerbations (primary outcome) and a significant improvement in CAT™ score, with no difference in the rate of healthcare contacts or pneumonias. However, basing recommendations on these results is difficult because of the heterogeneity of treatments reported in the usual care group, the higher rate of treatment changes in the group receiving the LABA/ICS combination of interest, and the medical practice patterns unique to the UK region where the study was conducted.\(^{106}\)

**Blood eosinophil count.** A number of recent studies have shown that blood eosinophil counts predict the magnitude of the effect of ICS (added on top of regular maintenance bronchodilator treatment) in preventing future exacerbations.\(^{97,107-111}\) There is a continuous relationship between blood eosinophil counts and ICS effects; no and/or small effects are observed at lower eosinophil counts, with incrementally increasing effects observed at higher eosinophil counts. Data modelling indicates that ICS containing regimens have little or no effect at a blood eosinophil count < 100 cells/µL,\(^{107}\) therefore this threshold can be used to identify patients with a low likelihood of treatment benefit with ICS. The threshold of a blood eosinophil count > 300 cells/µL identifies the top of the continuous relationship between eosinophils and ICS, and can be used to identify patients with the greatest likelihood of treatment benefit with ICS. All in all, therefore, blood eosinophil counts can help clinicians estimate the likelihood of a beneficial preventive response to the addition of ICS to regular bronchodilator treatment, and thus can be used as a biomarker in conjunction with clinical assessment when making decisions regarding ICS use.

Sources of evidence include:
1) *Post-hoc* analyses comparing ICS/LABA versus LABA\(^ {107,108,110}\)
2) Pre-specified analyses comparing triple therapy versus LAMA/LABA or LAMA\(^ {115,127,129}\)
3) Other analyses comparing ICS/LABA versus LABA/LAMA\(^ {112}\) or studying ICS withdrawal.\(^ {113-115}\)

The treatment effect of ICS containing regimens (ICS/LAMA/LABA and ICS/LABA vs LABA/LAMA) is higher in patients with high exacerbation risk (≥ 2 exacerbations and / or 1 hospitalization in the previous year).\(^ {96,97,109}\) Thus, the use of blood eosinophil counts to predict ICS effects should always be combined with clinical assessment of exacerbation risk (as indicated by the previous history of exacerbations). Other factors (smoking status, ethnicity, geographical location) could influence the relationship between ICS effect and blood eosinophil count, but remains to be further explored. The mechanism for an increased ICS effect in COPD patients with higher blood eosinophil counts remains unclear.

The repeatability of blood eosinophil counts in a large primary care population appears reasonable,\(^ {116}\) although greater variability is observed at higher thresholds.\(^ {117}\) Better reproducibility is observed at the lower thresholds (e.g., 100 cells/µL).\(^ {118}\)
Cohort studies have produced differing results with regard to the ability of blood eosinophils to predict future exacerbation outcomes, with either no relationship\textsuperscript{119} or a positive relationship reported.\textsuperscript{120,121} Differences between studies are likely to be related to different previous exacerbation histories and ICS use. There is insufficient evidence to recommend that blood eosinophils should be used to predict future exacerbation risk on an individual basis in COPD patients.

**Adverse effects.** There is high quality evidence from randomized controlled trials (RCTs) that ICS use is associated with higher prevalence of oral candidiasis, hoarse voice, skin bruising and pneumonia.\textsuperscript{100} This excess risk has been confirmed in ICS studies using fluticasone furoate, even at low doses.\textsuperscript{122} Patients at higher risk of pneumonia include those who currently smoke, are aged $\geq 55$ years, have a history of prior exacerbations or pneumonia, a body mass index (BMI) $< 25$ kg/m$^2$, a poor MRC dyspnea grade and/or severe airflow limitation.\textsuperscript{123,124} Independent of ICS use, there is evidence that a blood eosinophil count $< 2\%$ increases the risk of developing pneumonia.\textsuperscript{125} In studies of patients with moderate COPD, ICS by itself or in combination with a LABA did not increase the risk of pneumonia.\textsuperscript{102,124}

Results from RCTs have yielded varied results regarding the risk of decreased bone density and fractures with ICS treatment, which may be due to differences in study designs and/or differences between ICS compounds.\textsuperscript{42,122,126-128} Results of observational studies suggest that ICS treatment could also be associated with increased risk of diabetes/poor control of diabetes,\textsuperscript{129} cataracts,\textsuperscript{130} and mycobacterial infection\textsuperscript{131} including tuberculosis.\textsuperscript{132,133} In the absence of RCT data on these issues, it is not possible to draw firm conclusions.\textsuperscript{134} An increased risk of tuberculosis has been found in both observational studies and a meta-analysis of RCTs.\textsuperscript{124,125}

**Withdrawal of ICS.** Results from withdrawal studies provide equivocal results regarding consequences of withdrawal on lung function, symptoms and exacerbations.\textsuperscript{135-139} Some studies, but not all, have shown an increase in exacerbations and/or symptoms following ICS withdrawal, while others have not. There has been evidence for a modest decrease in FEV$_1$ (approximately 40 mL) with ICS withdrawal,\textsuperscript{139} which could be associated with increased baseline circulating eosinophil level.\textsuperscript{113} A recent study examining ICS withdrawal on a background of dual bronchodilator therapy demonstrated that both FEV$_1$ loss and an increase in exacerbation frequency associated with ICS withdrawal was greatest among patients with a blood eosinophil count $\geq 300$ cells/$\mu$L at baseline.\textsuperscript{115} Differences between studies may relate to differences in methodology, including the use of background long-acting bronchodilator medication(s) which may minimize any effect of ICS withdrawal.
**Triple inhaled therapy**

The step up in inhaled treatment to LABA plus LAMA plus ICS (triple therapy) can occur by various approaches.\(^{140}\) This may improve lung function, patient reported outcomes and prevent exacerbations.\(^{141-144}\) Adding a LAMA to existing LABA/ICS improves lung function and patient reported outcomes, in particular exacerbation risk.\(^{142,145-148}\) A double-blind, parallel group, RCT reported that treatment with single inhaler triple therapy had greater clinical benefits compared to tiotropium in patients with symptomatic COPD, FEV\(_1\) < 50%, and a history of exacerbations\(^{111}\) but double-blind RCTs have reported benefits of single-inhaler triple therapy compared with LABA/LAMA combination therapy.\(^{97,109}\)

**Oral glucocorticoids**

Oral glucocorticoids have numerous side effects, including steroid myopathy\(^{149}\) which can contribute to muscle weakness, decreased functionality, and respiratory failure in subjects with very severe COPD. Systemic glucocorticoids for treating acute exacerbations in hospitalized patients, or during emergency department visits, have been shown to reduce the rate of treatment failure, the rate of relapse and improve lung function and breathlessness.\(^{150}\) Conversely, prospective studies on the long-term effects of oral glucocorticoids in stable COPD are limited\(^{151,152}\). Therefore, while oral glucocorticoids play a role in the acute management of exacerbations, they have no role in the chronic daily treatment in COPD because of a lack of benefit balanced against a high rate of systemic complications.

**Phosphodiesterase-4 (PDE4) inhibitors**

**Efficacy.** The principal action of PDE4 inhibitors is to reduce inflammation by inhibiting the breakdown of intracellular cyclic AMP.\(^{153}\) Roflumilast is a once daily oral medication with no direct bronchodilator activity. Roflumilast reduces moderate and severe exacerbations treated with systemic corticosteroids in patients with chronic bronchitis, severe to very severe COPD, and a history of exacerbations.\(^{154}\) The effects on lung function are also seen when roflumilast is added to long-acting bronchodilators\(^{155}\) and in patients who are not controlled on fixed-dose LABA/ICS combinations.\(^{156}\) The beneficial effects of roflumilast have been reported to be greater in patients with a prior history of hospitalization for an acute exacerbation.\(^{157,158}\) There has been no study directly comparing roflumilast with an inhaled corticosteroid.

**Adverse effects.** PDE4 inhibitors have more adverse effects than inhaled medications for COPD.\(^{159}\) The most frequent are diarrhea, nausea, reduced appetite, weight loss, abdominal pain, sleep disturbance, and headache. Roflumilast should also be used with caution in patients with depression.

**Antibiotics**

- In older studies prophylactic, continuous use of antibiotics had no effect on the frequency of exacerbations in COPD\(^{160,161}\) and a study that examined the efficacy of chemoprophylaxis undertaken in winter months over a period of 5 years concluded that there was no benefit.\(^{162}\)
- More recent studies have shown that regular use of some antibiotics may reduce
exacerbation rate.\textsuperscript{163,164}

- Azithromycin (250 mg/day or 500 mg three times per week) or erythromycin (500 mg two times per day) for one year in patients prone to exacerbations reduced the risk of exacerbations compared to usual care.\textsuperscript{165-167}

Adverse effects. Azithromycin use was associated with an increased incidence of bacterial resistance, prolongation of QTc interval, and impaired hearing tests.\textsuperscript{167}

Mucolytic (mucokinetics, mucoregulators) and antioxidant agents (NAC, carbocysteine)

- In COPD patients not receiving inhaled corticosteroids, regular treatment with mucolytics such as erdosteine, carbocysteine and N-acetylcysteine may reduce exacerbations and modestly improve health status.\textsuperscript{168-170}

Issues related to inhaled delivery

THE INHALED ROUTE

- When a treatment is given by the inhaled route, the importance of education and training in inhaler device technique cannot be over-emphasized.
- The choice of inhaler device has to be individually tailored and will depend on access, cost, prescriber, and most importantly, patient’s ability and preference.
- It is essential to provide instructions and to demonstrate the proper inhalation technique when prescribing a device, to ensure that inhaler technique is adequate, and re-check at each visit that patients continue to use their inhaler correctly.
- Inhaler technique (and adherence to therapy) should be assessed before concluding that the current therapy is insufficient.

Other pharmacological treatments

OTHER PHARMACOLOGICAL TREATMENTS

**ALPHA-1 ANTITRYPsin AUGMENTATION THERAPY**

- Intravenous augmentation therapy may slow down the progression of emphysema (Evidence B).

**ANTITUSIVES**

- There is no conclusive evidence of a beneficial role of antitussives in patients with COPD (Evidence C).

**VASODILATORS**

- Vasodilators do not improve outcomes and may worsen oxygenation (Evidence B).
REHABILITATION, EDUCATION & SELF-MANAGEMENT

Pulmonary rehabilitation

Pulmonary rehabilitation is defined as “a comprehensive intervention based on thorough patient assessment followed by patient-tailored therapies that include, but are not limited to, exercise training, education, self-management intervention aiming at behavior change, designed to improve the physical and psychological condition of people with chronic respiratory disease and to promote the long-term adherence to health-enhancing behaviors.” The benefits to COPD patients from pulmonary rehabilitation are considerable (see Table), and rehabilitation has been shown to be the most effective therapeutic strategy to improve shortness of breath, health status and exercise tolerance.172

SUPPORTIVE, PALLIATIVE, END-OF-LIFE & HOSPICE CARE

Symptom control and palliative care

Palliative care is a broad term that encompasses approaches to symptom control as well as management of terminal patients close to death. The goal of palliative care is to prevent and relieve suffering, and to support the best possible quality of life for patients and their families, regardless of the stage of disease or the need for other therapies.173 Even when receiving optimal medical therapy many patients with COPD continue to experience distressing breathlessness, impaired exercise capacity, fatigue, and suffer panic, anxiety and depression (see Table).174
OTHER TREATMENTS

Oxygen therapy and ventilatory support

**Oxygen therapy.** The long-term administration of oxygen (> 15 hours per day) to patients with chronic respiratory failure has been shown to increase survival in patients with severe resting hypoxemia.\(^\text{175}\) Breathlessness may be relieved in COPD patients who are either mildly hypoxemic, or non-hypoxemic but do not otherwise qualify for home oxygen therapy, when oxygen is given during exercise training; however, studies have shown no improvement of breathlessness in daily life and no benefit on health related quality of life (see Table).\(^\text{176,177}\)

**Ventilatory Support**

*During exacerbations of COPD.* Noninvasive ventilation (NIV) in the form of noninvasive positive pressure ventilation (NPPV) is the standard of care for decreasing morbidity and mortality in patients hospitalized with an exacerbation of COPD and acute respiratory failure.\(^\text{178-180}\)

*Stable patient.* In patients with both COPD and obstructive sleep apnea there are clear benefits associated with the use of continuous positive airway pressure (CPAP) to improve both survival and the risk of hospital admissions.\(^\text{181}\)
Whether to use NPPV chronically at home to treat patients with acute on chronic respiratory failure following hospitalization remains undetermined and outcome may be affected by persistent hypercapnia. 

A recent multicenter (13 sites) prospective RCT of COPD patients (n=116) with persistent hypercapnia (PaCO₂ >53 mmHg) showed that adding home NIV to oxygen therapy significantly prolonged the time to readmission or death within 12 months.

Two previous retrospective studies and two of three RCTs reported reductions in re-hospitalization and improved survival with using NPPV post-hospitalization.

In patients with both COPD and obstructive sleep apnea there are clear benefits associated with the use of continuous positive airway pressure (CPAP) to improve both survival and the risk of hospital admissions.

Surgical Interventions

Lung volume reduction surgery (LVRS). LVRS is a surgical procedure in which parts of the lungs are resected to reduce hyperinflation, making respiratory muscles more effective pressure generators by improving their mechanical efficiency. LVRS increases the elastic recoil pressure of the lung and thus improves expiratory flow rates and reduces exacerbations.

Lung transplantation. In appropriately selected patients with very severe COPD, lung transplantation has been shown to improve health status and functional capacity but not prolong survival. Over 70% of lung transplants conducted in COPD patients are double lung transplants; the remainder are single lung transplants. Bilateral lung transplantation has been reported to provide longer survival than single lung transplantation in COPD patients, especially those < 60 years of age.

### INTERVENTIONAL THERAPY IN STABLE COPD

#### LUNG VOLUME REDUCTION SURGERY
- Lung volume reduction surgery improves survival in severe emphysema patients with an upper–lobe emphysema and low post–rehabilitation exercise capacity (Evidence A).

#### BULLECTOMY
- In selected patients bullectomy is associated with decreased dyspnea, improved lung function and exercise tolerance (Evidence C).

#### TRANSPLANTATION
- In appropriately selected patients with very severe COPD, lung transplantation has been shown to improve quality of life and functional capacity (Evidence C).

#### BRONCHOSCOPIC INTERVENTIONS
- In select patients with advanced emphysema, bronchoscopic interventions reduce end-expiratory lung volume and improves exercise tolerance, health status and lung function at 6-12 months following treatment. Endobronchial valves (Evidence B); Lung coils (Evidence B); Vapor ablation (Evidence B).
MANAGEMENT OF STABLE COPD

OVERALL KEY POINTS:

- The management strategy for stable COPD should be predominantly based on the individualized assessment of symptoms and future risk of exacerbations.
- All individuals who smoke should be strongly encouraged and supported to quit.
- The main treatment goals are reduction of symptoms and future risk of exacerbations.
- Management strategies are not limited to pharmacological treatments and should be complemented by appropriate non-pharmacological interventions.

Once COPD has been diagnosed, effective management should be based on an individualized assessment to reduce both current symptoms and future risks of exacerbations (see Table).

GOALS FOR TREATMENT OF STABLE COPD

- Relieve Symptoms
- Improve Exercise Tolerance
- Improve Health Status
  
  and
  
- Prevent Disease Progression
- Prevent and Treat Exacerbations
- Reduce Mortality

IDENTIFY AND REDUCE EXPOSURE TO RISK FACTORS

Identification and reduction of exposure to risk factors (see Tables)\textsuperscript{36,337,338} is important in the treatment and prevention of COPD. Cigarette smoking is the most commonly encountered and easily identifiable risk factor for COPD, and smoking cessation should be continually encouraged for all individuals who smoke. Reduction of total personal exposure to occupational dusts, fumes, and gases, and to indoor and outdoor air pollutants, should also be addressed.
Pharmacological therapies can reduce symptoms, and the risk and severity of exacerbations, as well as improve the health status and exercise tolerance of patients with COPD. Most of the drugs are inhaled so proper inhaler technique is highly relevant. Key points for the inhalation of drugs, bronchodilator use, the use of anti-inflammatory agents and the use of pharmacological treatments are summarized in the Tables.
KEY POINTS FOR INHALATION OF DRUGS

- The choice of inhaler device has to be individually tailored and will depend on access, cost, prescriber, and most importantly, patient’s ability and preference.

- It is essential to provide instructions and to demonstrate the proper inhalation technique when prescribing a device, to ensure that inhaler technique is adequate and re-check at each visit that patients continue to use their inhaler correctly.

- Inhaler technique (and adherence to therapy) should be assessed before concluding that the current therapy requires modification.

KEY POINTS FOR THE USE OF BRONCHODILATORS

- LABAs and LAMAs are preferred over short-acting agents except for patients with only occasional dyspnea (Evidence A), and for immediate relief of symptoms in patients already on long-acting bronchodilators for maintenance therapy.

- Patients may be started on single long-acting bronchodilator therapy or dual long-acting bronchodilator therapy. In patients with persistent dyspnea on one bronchodilator treatment should be escalated to two (Evidence A).

- Inhaled bronchodilators are recommended over oral bronchodilators (Evidence A).

- Theophylline is not recommended unless other long-term treatment bronchodilators are unavailable or unaffordable (Evidence B).

KEY POINTS FOR THE USE OF ANTI-INFLAMMATORY AGENTS

- Long-term monotherapy with ICS is not recommended (Evidence A).

- Long-term treatment with ICS may be considered in association with LABAs for patients with a history of exacerbations despite appropriate treatment with long-acting bronchodilators (Evidence A).

- Long-term therapy with oral corticosteroids is not recommended (Evidence A).

- In patients with exacerbations despite LABA/ICS or LABA/LAMA/ICS, chronic bronchitis and severe to very severe airflow obstruction, the addition of a PDE4 inhibitor can be considered (Evidence B).

- In former smokers with exacerbations despite appropriate therapy, macrolides, in particular azithromycin, can be considered (Evidence B).

- Statin therapy is not recommended for prevention of exacerbations (Evidence A).

- Antioxidant mucolytics are recommended only in selected patients (Evidence A).
Algorithms for the assessment, initiation and follow-up management of pharmacological treatment

A model for the INITIATION of pharmacological management of COPD according to the individualized assessment of symptoms and exacerbation risk following the ABCD assessment scheme is shown. There is a lack of high-quality evidence supporting initial pharmacological treatment strategies in newly diagnosed COPD patients. The Figure below is an attempt to provide clinical guidance using the best available evidence.

<table>
<thead>
<tr>
<th>Group C</th>
<th>≥ 2 moderate exacerbations or ≥ 1 leading to hospitalization</th>
<th>Group D</th>
<th>LAMA or LAMA + LABA* or ICS + LABA**</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>*Consider if highly symptomatic (e.g. CAT &gt; 20)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><strong>Consider if eos ≥ 300</strong></td>
</tr>
<tr>
<td>Group A</td>
<td>0 or 1 moderate exacerbations (not leading to hospital admission)</td>
<td>A Bronchodilator</td>
<td>mMRC 0-1 CAT &lt; 10</td>
</tr>
<tr>
<td>Group B</td>
<td>A Long Acting Bronchodilator (LABA or LAMA)</td>
<td></td>
<td>mMRC ≥ 2 CAT ≥ 10</td>
</tr>
</tbody>
</table>

**Definition of abbreviations:** eos: blood eosinophil count in cells per microliter; mMRC: modified Medical Research Council dyspnea questionnaire; CAT™: COPD Assessment Test™.

Following implementation of therapy, patients should be reassessed for attainment of treatment goals and identification of any barriers for successful treatment (see Figure below). Following review of the patient response to treatment initiation, adjustments in pharmacological treatment may be needed.
A separate algorithm is provided for **FOLLOW-UP** treatment, where the management is still based on symptoms and exacerbations, but the recommendations do not depend on the patient’s GOLD group at diagnosis (see next Figure). These follow-up recommendations are designed to facilitate management of patients taking maintenance treatment(s), whether early after initial treatment or after years of follow-up. These recommendations incorporate recent evidence from clinical trials and the use of peripheral blood eosinophil counts as a biomarker to guide the use of ICS therapy for exacerbation prevention.
The Figure above suggests escalation and de-escalation strategies based on available efficacy as well as safety data. The response to treatment escalation should always be reviewed, and de-escalation should be considered if there is a lack of clinical benefit and/or side effects occur. De-escalation may also be considered in COPD patients receiving treatment who return with resolution of some symptoms that subsequently may require less therapy. Patients, in whom treatment modification is considered, in particular de-escalation, should be undertaken under close medical supervision. We are fully aware that treatment escalation has not been systematically tested; trials of de-escalation are also limited and only include ICS.
*Initial pharmacological management*

Rescue short-acting bronchodilators should be prescribed to all patients for immediate symptom relief.

**Group A**

► All Group A patients should be offered bronchodilator treatment based on its effect on breathlessness. This can be either a short- or a long-acting bronchodilator.

► This should be continued if benefit is documented.

**Group B**

► Initial therapy should consist of a long acting bronchodilator. Long-acting inhaled bronchodilators are superior to short-acting bronchodilators taken as needed i.e., *pro re nata* (prn) and are therefore recommended.\(^{199,200}\)

► There is no evidence to recommend one class of long-acting bronchodilators over another for initial relief of symptoms in this group of patients. In the individual patient, the choice should depend on the patient’s perception of symptom relief.

► For patients with severe breathlessness initial therapy with two bronchodilators may be considered.\(^91\)

► Group B patients are likely to have comorbidities that may add to their symptomatology and impact their prognosis, and these possibilities should be investigated.\(^{201,202}\)

**Group C**

► Initial therapy should consist of a single long acting bronchodilator. In two head-to-head comparisons\(^{69,203}\) the tested LAMA was superior to the LABA regarding exacerbation prevention (for details see Chapter 3) therefore we recommend starting therapy with a LAMA in this group.

**Group D**

► In general, therapy can be started with a LAMA as it has effects on both breathlessness and exacerbations (see Chapter 3).

► For patients with more severe symptoms (order of magnitude of CAT™ ≥ 20), especially driven by greater dyspnea and / or exercise limitation, LAMA/LABA may be chosen as initial treatment based on studies with patient reported outcomes as the primary endpoint where LABA/LAMA combinations showed superior results compared to the single substances (see Chapter 3). An advantage of LABA/LAMA over LAMA for exacerbation prevention has not been consistently demonstrated, so the decision to use LABA/LAMA as initial treatment should be guided by the level of symptoms.

► In some patients, initial therapy with LABA/ICS may be the first choice; this treatment has the greatest likelihood of reducing exacerbations in patients with blood eosinophil counts ≥ 300 cells/µL.
LABA/ICS may also be first choice in COPD patients with a history of asthma.

► ICS may cause side effects such as pneumonia,\textsuperscript{123,203} so should be used as initial therapy only after the possible clinical benefits versus risks have been considered.

Follow-up pharmacological management

The follow-up pharmacological treatment algorithm can be applied to any patient who is already taking maintenance treatment(s) irrespective of the GOLD group allocated at treatment initiation. The need to treat primarily dyspnea/exercise limitation or prevent exacerbations further should be evaluated. If a change in treatment is considered necessary then select the corresponding algorithm for dyspnea or exacerbations; the exacerbation algorithm should also be used for patients who require a change in treatment for both dyspnea and exacerbations. Identify which box corresponds to the patient’s the current treatment.

Follow up pharmacological management should be guided by the principles of first review and assess, then adjust if needed:

► Review
  ▪ Review symptoms (dyspnea) and exacerbation risk.
► Assess
  ▪ Assess inhaler technique and adherence, and the role of non-pharmacological approaches (covered later in this chapter).
► Adjust
  ▪ Adjust pharmacological treatment, including escalation or de-escalation. Switching inhaler device or molecules within the same class (e.g. using a different long acting bronchodilator) may be considered as appropriate. Any change in treatment requires a subsequent review of the clinical response, including side effects.

Dyspnea

► For patients with persistent breathlessness or exercise limitation on long acting bronchodilator monotherapy,\textsuperscript{204} the use of two bronchodilators is recommended.
  ▪ If the addition of a second long acting bronchodilator does not improve symptoms, we suggest the treatment could be stepped down again to monotherapy. Switching inhaler device or molecules can also be considered.
► For patients with persistent breathlessness or exercise limitation on LABA/ICS treatment, LAMA can be added to escalate to triple therapy.
  ▪ Alternatively, switching from LABA/ICS to LABA/LAMA should be considered if the original indication for ICS was inappropriate (e.g., an ICS was used to treat symptoms in the absence of a history of exacerbations), or there has been a lack of response to ICS treatment, or if ICS side effects warrant discontinuation.
► At all stages, dyspnea due to other causes (not COPD) should be investigated and treated
appropriately. Inhaler technique and adherence should be considered as causes of inadequate treatment response.

**Exacerbations**

- For patients with persistent exacerbations on *long acting bronchodilator* monotherapy, escalation to either LABA/LAMA or LABA/ICS is recommended. LABA/ICS may be preferred for patients with a history or findings suggestive of asthma. Blood eosinophil counts may identify patients with a greater likelihood of a beneficial response to ICS. For patients with one exacerbation per year, a peripheral blood level ≥ 300 eosinophils/µL identifies patients more likely to respond to LABA/ICS treatment.\(^{107,108}\) For patients with ≥ 2 moderate exacerbations per year or at least one severe exacerbation requiring hospitalization in the prior year, LABA/ICS treatment can be considered at blood eosinophil counts ≥ 100 cells/µL, as ICS effects are more pronounced in patients with greater exacerbation frequency and/or severity.\(^{97}\)

- In patients who develop further exacerbations on LABA/LAMA therapy we suggest two alternative pathways. Blood eosinophil counts < 100 cells/µL can be used to predict a low likelihood of a beneficial ICS response:
  - Escalation to LABA/LAMA/ICS. A beneficial response after the addition of ICS may be observed at blood eosinophil counts ≥ 100 cells/µL, with a greater magnitude of response more likely with higher eosinophil counts.
  - Add roflumilast or azithromycin (see below) if blood eosinophils < 100 cells/µL.

- In patients who develop further exacerbations on LABA/ICS therapy, we recommend escalation to triple therapy by adding a LAMA.\(^{97,147}\) Alternatively, treatment can be switched to LABA/LAMA if there has been a lack of response to ICS treatment, or if ICS side effects warrant discontinuation.

- If patients treated with LABA/LAMA/ICS who still have exacerbations the following options may be considered:
  - **Add roflumilast.** This may be considered in patients with an FEV\(_1\) < 50% predicted and chronic bronchitis,\(^{156}\) particularly if they have experienced at least one hospitalization for an exacerbation in the previous year.\(^{157,205}\)
  - **Add a macrolide.** The best available evidence exists for the use of azithromycin, especially in those who are not current smokers.\(^{158,167}\) Consideration to the development of resistant organisms should be factored into decision-making.
  - **Stopping ICS.** This can be considered if there are adverse effects (such as pneumonia) or a reported lack of efficacy. However, a blood eosinophil count ≥ 300 cells/µL identifies patients with the greatest likelihood of experiencing more exacerbations after ICS withdrawal and who subsequently should be followed closely for relapse of exacerbations.\(^{114,115}\)
TREATMENT OF STABLE COPD: NON-PHARMACOLOGICAL TREATMENT

Education and self-management

Self-management education and coaching by healthcare professionals should be a major component of the “Chronic Care Model” within the context of the healthcare delivery system. The aim of self-management interventions is to motivate, engage and coach the patients to positively adapt their health behavior(s) and develop skills to better manage their disease on a day-to-day basis.\(^{206}\)

Physicians and healthcare providers need to go beyond pure education/advice-giving (didactic) approaches to help patients learn and adopt sustainable self-management skills. In addition to addressing behavioral risk factors (i.e., smoking, diet, exercise), self-management should involve patients in monitoring and managing the signs and symptoms of their disease, being adherent to treatment (including to medications and other medical advice), maintaining regular contact with healthcare providers, and managing the psychosocial consequences of their condition.

<table>
<thead>
<tr>
<th>NON-PHARMACOLOGIC MANAGEMENT OF COPD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PATIENT GROUP</strong></td>
</tr>
<tr>
<td>A</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>B-D</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
Oxygen therapy

An appropriate algorithm for the prescription of oxygen to COPD patients is shown below.

**PRESCRIPTION OF SUPPLEMENTAL OXYGEN TO COPD PATIENTS**

Arterial hypoxemia defined as:
- \( \text{PaO}_2 < 55 \text{ mmHg (8 kPa)} \) or \( \text{SaO}_2 < 88\% \)
- or
- \( \text{PaO}_2 > 55 \text{ but } < 60 \text{ mmHg (> 7.3 kPa but < 8 kPa)} \)
- with right heart failure or erythrocytosis

Prescribe supplemental oxygen and titrate to keep \( \text{SaO}_2 \geq 90\% \)

Recheck in 60 to 90 days to assess:
- if supplemental oxygen is still indicated
- if prescribed supplemental oxygen is effective
Key points for the use of non-pharmacological treatments are given in the following Table.

<table>
<thead>
<tr>
<th>Key Points for the Use of Non-Pharmacological Treatments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Education, Self-Management and Pulmonary Rehabilitation</strong></td>
</tr>
<tr>
<td>- Education is needed to change patient’s knowledge but there is no evidence that used alone it will change patient behavior.</td>
</tr>
<tr>
<td>- Education self-management with the support of a case manager with or without the use of a written action plan is recommended for the prevention of exacerbation complications such as hospital admissions (Evidence B).</td>
</tr>
<tr>
<td>- Rehabilitation is indicated in all patients with relevant symptoms and/or a high risk for exacerbation (Evidence A).</td>
</tr>
<tr>
<td>- Physical activity is a strong predictor of mortality (Evidence A). Patients should be encouraged to increase the level of physical activity although we still don’t know how to best insure the likelihood of success.</td>
</tr>
<tr>
<td><strong>Vaccination</strong></td>
</tr>
<tr>
<td>- Influenza vaccination is recommended for all patients with COPD (Evidence A).</td>
</tr>
<tr>
<td>- Pneumococcal vaccination: the PCV13 and PPSSV23 are recommended for all patients &gt; 65 years of age, and in younger patients with significant comorbid conditions including chronic heart or lung disease (Evidence B).</td>
</tr>
<tr>
<td><strong>Nutrition</strong></td>
</tr>
<tr>
<td>- Nutritional supplementation should be considered in malnourished patients with COPD (Evidence B).</td>
</tr>
<tr>
<td><strong>End of Life and Palliative Care</strong></td>
</tr>
<tr>
<td>- All clinicians managing patients with COPD should be aware of the effectiveness of palliative approaches to symptom control and use these in their practice (Evidence D).</td>
</tr>
<tr>
<td>- End of life care should include discussions with patients and their families about their views on resuscitation, advance directives and place of death preferences (Evidence D).</td>
</tr>
<tr>
<td><strong>Treatment of Hypoxemia</strong></td>
</tr>
<tr>
<td>- In patients with severe resting hypoxemia long-term oxygen therapy is indicated (Evidence A).</td>
</tr>
<tr>
<td>- In patients with stable COPD and resting or exercise-induced moderate desaturation, long term oxygen treatment should not be routinely prescribed. However, individual patient factors may be considered when evaluating the patient’s needs for supplemental oxygen (Evidence A).</td>
</tr>
<tr>
<td>- Resting oxygenation at sea level does not exclude the development of severe hypoxemia when travelling by air (Evidence C).</td>
</tr>
<tr>
<td><strong>Treatment of Hypercapnia</strong></td>
</tr>
<tr>
<td>- In patients with severe chronic hypercapnia and a history of hospitalization for acute respiratory failure, long term noninvasive ventilation may be considered (Evidence B).</td>
</tr>
<tr>
<td><strong>Intervention Bronchoscopy and Surgery</strong></td>
</tr>
<tr>
<td>- Lung volume reduction surgery should be considered in selected patients with upper-lobe emphysema (Evidence A).</td>
</tr>
<tr>
<td>- Bronchoscopic lung volume reduction interventions may be considered in selected patients with advanced emphysema (Evidence B).</td>
</tr>
<tr>
<td>- In selected patients with a large bulla surgical bullectomy may be considered (Evidence C).</td>
</tr>
<tr>
<td>- In patients with very severe COPD (progressive disease, BODE score of 7 to 10, and not candidate for lung volume reduction) lung transplantation may be considered for referral with at least one of the following: (1) history of hospitalization for exacerbation associated with acute hypercapnia (Paco₂ &gt;50 mm Hg); (2) pulmonary hypertension and/or cor pulmonale, despite oxygen therapy; or (3) FEV₁ &lt; 20% and either DLCO &lt; 20% or homogenous distribution of emphysema (Evidence C).</td>
</tr>
</tbody>
</table>
MONITORING AND FOLLOW-UP

Routine follow-up of COPD patients is essential. Lung function may worsen over time, even with the best available care. Symptoms, exacerbations and objective measures of airflow limitation should be monitored to determine when to modify management and to identify any complications and/or comorbidities that may develop. Based on current literature, comprehensive self-management or routine monitoring has not shown long-term benefits in terms of health status over usual care alone for COPD patients in general practice. 207

MANAGEMENT OF EXACERBATIONS

OVERALL KEY POINTS:

- An exacerbation of COPD is defined as an acute worsening of respiratory symptoms that results in additional therapy.

- Exacerbations of COPD can be precipitated by several factors. The most common causes are respiratory tract infections.

- The goal for treatment of COPD exacerbations is to minimize the negative impact of the current exacerbation and to prevent subsequent events.

- Short-acting inhaled beta2-agonists, with or without short-acting anticholinergics, are recommended as the initial bronchodilators to treat an acute exacerbation.

- Maintenance therapy with long-acting bronchodilators should be initiated as soon as possible before hospital discharge.

- Systemic corticosteroids can improve lung function (FEV1), oxygenation and shorten recovery time and hospitalization duration. Duration of therapy should not be more than 5-7 days.

- Antibiotics, when indicated, can shorten recovery time, reduce the risk of early relapse, treatment failure, and hospitalization duration. Duration of therapy should be 5-7 days.

- Methylxanthines are not recommended due to increased side effect profiles.

- Non-invasive mechanical ventilation should be the first mode of ventilation used in COPD patients with acute respiratory failure who have no absolute contraindication because it improves gas exchange, reduces work of breathing and the need for intubation, decreases hospitalization duration and improves survival.

- Following an exacerbation, appropriate measures for exacerbation prevention should be initiated.
COPD exacerbations are defined as an acute worsening of respiratory symptoms that result in additional therapy.\textsuperscript{208,209}

They are classified as:

- Mild (treated with short acting bronchodilators only, SABDs)
- Moderate (treated with SABDs plus antibiotics and/or oral corticosteroids) or
- Severe (patient requires hospitalization or visits the emergency room). Severe exacerbations may also be associated with acute respiratory failure.

Exacerbations of chronic obstructive pulmonary disease (COPD) are important events in the management of COPD because they negatively impact health status, rates of hospitalization and readmission, and disease progression.\textsuperscript{208,209} COPD exacerbations are complex events usually associated with increased airway inflammation, increased mucus production and marked gas trapping. These changes contribute to increased dyspnea that is the key symptom of an exacerbation. Other symptoms include increased sputum purulence and volume, together with increased cough and wheeze.\textsuperscript{210} As comorbidities are common in COPD patients, exacerbations must be differentiated clinically from other events such as acute coronary syndrome, worsening congestive heart failure, pulmonary embolism and pneumonia.

**TREATMENT OPTIONS**

**Treatment setting**

The goals of treatment for COPD exacerbations are to minimize the negative impact of the current exacerbation and prevent the development of subsequent events.\textsuperscript{211} Depending on the severity of an exacerbation and/or the severity of the underlying disease, an exacerbation can be managed in either the outpatient or inpatient setting. More than 80% of exacerbations are managed on an outpatient basis with pharmacological therapies including bronchodilators, corticosteroids, and antibiotics.\textsuperscript{15,23,24}

When patients with a COPD exacerbation come to the emergency department, they should be provided with supplemental oxygen and undergo assessment to determine whether the exacerbation is life-threatening and if increased work of breathing or impaired gas exchange requires consideration for non-invasive ventilation (see Table). If so, healthcare providers should consider admission to the respiratory or intensive care unit of the hospital. Otherwise, the patient may be managed in the emergency department or hospital ward unit. In addition to pharmacological therapy, hospital management of exacerbations includes respiratory support (oxygen therapy, ventilation). The management of severe, but not life-threatening, exacerbations is also outlined (see Table).
The clinical presentation of COPD exacerbation is heterogeneous, thus we recommend that in hospitalized patients the severity of the exacerbation should be based on the patient’s clinical signs and recommend the following classification.\textsuperscript{212}

\textbf{No respiratory failure}: Respiratory rate: 20-30 breaths per minute; no use of accessory respiratory muscles; no changes in mental status; hypoxemia improved with supplemental oxygen given via Venturi mask 28-35% inspired oxygen (FiO\textsubscript{2}); no increase in PaCO\textsubscript{2}. 
Acute respiratory failure – non-life-threatening: Respiratory rate: > 30 breaths per minute; using accessory respiratory muscles; no change in mental status; hypoxemia improved with supplemental oxygen via Venturi mask 25-30% FiO₂; hypercarbia i.e., PaCO₂ increased compared with baseline or elevated 50-60 mmHg.

Acute respiratory failure – life-threatening: Respiratory rate: > 30 breaths per minute; using accessory respiratory muscles; acute changes in mental status; hypoxemia not improved with supplemental oxygen via Venturi mask or requiring FiO₂ > 40%; hypercarbia i.e., PaCO₂ increased compared with baseline or elevated > 60 mmHg or the presence of acidosis (pH ≤ 7.25).

A recent updated Cochrane review concluded that the use of COPD exacerbation action plans with a single short educational component, in conjunction with ongoing support, reduced in-hospital healthcare utilization. Such educational interventions were also found to increase the treatment of COPD exacerbations with corticosteroids and antibiotics.²¹³

The three classes of medications most commonly used for COPD exacerbations are bronchodilators, corticosteroids, and antibiotics (see Table).

**KEY POINTS FOR THE MANAGEMENT OF EXACERBATIONS**

- Short-acting inhaled beta₂-agonists, with or without short-acting anticholinergics, are recommended as the initial bronchodilators to treat an acute exacerbation (Evidence C).
- Systemic corticosteroids can improve lung function (FEV₁), oxygenation and shorten recovery time and hospitalization duration. Duration of therapy should not be more than 5-7 days (Evidence A).
- Antibiotics, when indicated, can shorten recovery time, reduce the risk of early relapse, treatment failure, and hospitalization duration. Duration of therapy should be 5-7 days (Evidence B).
- Methylxanthines are not recommended due to increased side effect profiles (Evidence B).
- Non-invasive mechanical ventilation should be the first mode of ventilation used in COPD patients with acute respiratory failure who have no absolute contraindication because it improves gas exchange, reduces work of breathing and the need for intubation, decreases hospitalization duration and improves survival (Evidence A).

**Respiratory support**

**Oxygen therapy.** This is a key component of hospital treatment of an exacerbation. Supplemental oxygen should be titrated to improve the patient’s hypoxemia with a target saturation of 88-92%.²¹⁴ Once oxygen is started, blood gases should be checked frequently to ensure satisfactory oxygenation without carbon dioxide retention and/or worsening acidosis. Venturi masks (high-flow devices) offer more accurate and controlled delivery of oxygen than do nasal prongs.²¹⁵

**High-flow oxygen therapy by nasal cannula.** In patients with acute hypoxic respiratory failure, high-flow oxygen therapy by nasal cannula (HFNC) may be an alternative to standard oxygen therapy or noninvasive positive pressure ventilation; some studies have shown that HFNC can reduce the need for intubation or mortality in patients with acute hypoxic respiratory failure (ARF).²¹⁶
**Ventilatory Support.** Some patients need immediate admission to the respiratory care or intensive care unit (ICU) (see Table). Admission of patients with severe exacerbations to intermediate or special respiratory care units may be appropriate if adequate personnel skills and equipment exist to identify and manage acute respiratory failure. Ventilatory support in an exacerbation can be provided by either noninvasive (nasal or facial mask) or invasive (oro-tracheal tube or tracheostomy) ventilation. Respiratory stimulants are not recommended for acute respiratory failure. 217

---

**INDICATIONS FOR RESPIRATORY OR MEDICAL INTENSIVE CARE UNIT ADMISSION**

- Severe dyspnea that responds inadequately to initial emergency therapy.
- Changes in mental status (confusion, lethargy, coma).
- Persistent or worsening hypoxemia (PaO2 < 5.3 kPa or 40 mmHg) and/or severe/worsening respiratory acidosis (pH < 7.25) despite supplemental oxygen and noninvasive ventilation.
- Need for invasive mechanical ventilation.
- Hemodynamic instability - need for vasopressors.

*Local resources need to be considered.

**Noninvasive mechanical ventilation.** The use of noninvasive mechanical ventilation (NIV) is preferred over invasive ventilation (intubation and positive pressure ventilation) as the initial mode of ventilation to treat acute respiratory failure in patients hospitalized for acute exacerbations of COPD. NIV has been studied in RCTs showing a success rate of 80-85% (see Table). 179, 218-221

**Invasive mechanical ventilation.** The indications for initiating invasive mechanical ventilation during an exacerbation are shown in the Table, and include failure of an initial trial of NIV. 222

---

**INDICATIONS FOR NONINVASIVE MECHANICAL VENTILATION (NIV)**

At least one of the following:

- Respiratory acidosis (PaCO2 ≥ 6.0 kPa or 45 mmHg and arterial pH ≤ 7.35).
- Severe dyspnea with clinical signs suggestive of respiratory muscle fatigue, increased work of breathing, or both, such as use of respiratory accessory muscles, paradoxical motion of the abdomen, or retraction of the intercostal spaces.
- Persistent hypoxemia despite supplemental oxygen therapy.
Hospital discharge and follow-up

The cause, severity, impact, treatment and time course of exacerbations varies from patient to patient and facilities in the community, and healthcare systems, differ from country to country. Accordingly, there are no standards that can be applied to the timing and nature of discharge. When features related to re-hospitalization and mortality have been studied, defects in perceived optimal management have been identified including spirometric assessment and arterial blood gas analysis. Mortality relates to patient age, the presence of acidotic respiratory failure, the need for ventilatory support and comorbidities including anxiety and depression (see Table).
DISCHARGE CRITERIA AND RECOMMENDATIONS FOR FOLLOW-UP

- Full review of all clinical and laboratory data.
- Check maintenance therapy and understanding.
- Reassess inhaler technique.
- Ensure understanding of withdrawal of acute medications (steroids and/or antibiotics).
- Assess need for continuing any oxygen therapy.
- Provide management plan for comorbidities and follow-up.
- Ensure follow-up arrangements: early follow-up < 4 weeks, and late follow-up < 12 weeks as indicated.
- All clinical or investigational abnormalities have been identified.

1 – 4 WEEKS FOLLOW-UP

- Evaluate ability to cope in his/her usual environment.
- Review and understanding treatment regimen.
- Reassessment of inhaler techniques.
- Reassess need for long-term oxygen.
- Document the capacity to do physical activity and activities of daily living.
- Document symptoms: CAT or mMRC.
- Determine status of comorbidities.

12 – 16 WEEKS FOLLOW-UP

- Evaluate ability to cope in his/her usual environment.
- Review understanding treatment regimen.
- Reassessment of inhaler techniques.
- Reassess need for long-term oxygen.
- Document the capacity to do physical activity and activities of daily living.
- Measure spirometry: FEV₁.
- Document symptoms: CAT or mMRC.
- Determine status of comorbidities.
Prevention of exacerbations

After an acute exacerbation, appropriate measures for prevention of further exacerbations should be initiated (see Table).

<table>
<thead>
<tr>
<th>INTERVENTION CLASS</th>
<th>INTERVENTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bronchodilators</td>
<td>LABAs</td>
</tr>
<tr>
<td></td>
<td>LAMAs</td>
</tr>
<tr>
<td></td>
<td>LABA + LAMA</td>
</tr>
<tr>
<td>Corticosteroid-containing regimens</td>
<td>LABA + ICS</td>
</tr>
<tr>
<td></td>
<td>LABA + LAMA + ICS</td>
</tr>
<tr>
<td>Anti-inflammatory (non-steroid)</td>
<td>Roflumilast</td>
</tr>
<tr>
<td>Anti-infectives</td>
<td>Vaccines</td>
</tr>
<tr>
<td></td>
<td>Long term Macrolides</td>
</tr>
<tr>
<td>Mucoregulators</td>
<td>N-acetylcysteine</td>
</tr>
<tr>
<td></td>
<td>Carbocysteine</td>
</tr>
<tr>
<td>Various Others</td>
<td>Smoking Cessation</td>
</tr>
<tr>
<td></td>
<td>Rehabilitation</td>
</tr>
<tr>
<td></td>
<td>Lung Volume Reduction</td>
</tr>
</tbody>
</table>
OVERALL KEY POINTS:

- COPD often coexists with other diseases (comorbidities) that may have a significant impact on disease course.
- In general, the presence of comorbidities should not alter COPD treatment and comorbidities should be treated per usual standards regardless of the presence of COPD.
- Lung cancer is frequently seen in patients with COPD and is a main cause of death.
- Cardiovascular diseases are common and important comorbidities in COPD.
- Osteoporosis and depression/anxiety are frequent, important comorbidities in COPD, are often under-diagnosed, and are associated with poor health status and prognosis.
- Gastroesophageal reflux (GERD) is associated with an increased risk of exacerbations and poorer health status.
- When COPD is part of a multimorbidity care plan, attention should be directed to ensure simplicity of treatment and to minimize polypharmacy.

REFERENCES

The full list of references for this pocket guide can be found online at:
www.goldcopd.org/pocketguidereferences